Menopausal Hot Flashes Treatment Market Global Industry Size, Share, Growth, Forecasts to 2022-2030

Treatment Options Targeting Brain’s Thermostat Lead to Innovations in Non-hormonal Drugs

High prevalence of fluctuating estrogen levels and depleting musculoskeletal health among women are some of the key drivers contributing to the robust growth of the menopausal hot flashes treatment market. Hence, healthcare companies are increasing their clinical trials in non-hormonal products to meet various cases. Recently, in January 2020, the U.K.-based clinical-stage biotech company KaNDy Therapeutics, announced positive data of their Phase 2b “SWITCH-1” clinical trial of their novel lead non-hormonal drug candidate, NT-814, for the treatment of menopause. Though the hormonal treatment type segment is expected to lead the menopausal hot flashes treatment market, non-hormonal treatment type segment is anticipated for exponential growth during the forecast period.

Get the sample copy of report@ https://qyresearchmedical.com/sample/111711

Companies in the market for menopausal hot flashes are increasing R&D in treatment options that target the brain’s thermostat to reduce incidence of hot flashes in women. Such innovations are creating value-grab opportunities for companies in the market menopausal hot flashes treatment market, whilst improving the quality of life of postmenopausal women.

Femtech to Explore Untapped Potential in Women’s Midlife Health Issues

The menopausal hot flashes treatment market is expected to grow at a CAGR of 6% during the forecast period. Most women from Generation X are now in their 40s and are technologically proficient. Likewise, online drug sales is anticipated to flourish in the market for menopausal hot flashes. However, there is a lack of interest from the femtech toward solving the issues of women’s midlife health issues.

The femtech sector has been more active toward solving the issues of menstrual health and pregnancy. However, there is a growing need for attention toward women’s midlife health issues such as menopausal hot flashes. Hence, companies are exploring untapped opportunities to address the stigma and associated silence pertaining to symptoms of menopause.

Companies in the menopausal hot flashes treatment market are targeting digitally literate women to create awareness about the issues related to menopause through social media. They are increasing their efficacy in complementary and alternative medicine (CAM) for management of hot flashes.

Innovations in Devices Attract Healthcare Companies

Apart from innovations in medicines, companies in the menopausal hot flashes treatment market are recommending women toward lifestyle modifications through online media channels. Likewise, companies are developing cutting-edge devices that suit the needs of women. For instance, the introduction of the Menopod™ has led to the growth of market for menopausal hot flashes, owing to its compact computer mouse-like shape and portability. The advent of smartwatch-like devices that act as a personal thermostat for women is also driving the global market.

Due to high prevalence of tech-savvy women in their late 40s, companies in the market for menopausal hot flashes are unearthing value opportunities with the development of mobile apps. These mobile apps are providing healthcare companies with important insights about the frequency of hot flashes in women. On the other hand, companies in the menopausal hot flashes treatment market are increasing research in customizable mattresses that offer cooling and heating temperature controls.

View full report@ https://qyresearchmedical.com/report/menopausal-hot-flashes-treatment-market-treatment-type-hormonal-treatment-estrogen-progesterone-and-estrogen-progesterone-combination-non-hormonal-treatment-antidepressant-gabapentin-pregabalin-and-clon-019-2030/111711

Cognitive Behavior Therapy Proves Effective in Addressing Complications Associated with Hot Flashes

The demand for nonpharmacologic treatment options is projected to escalate in the menopausal hot flashes treatment market. Thus, healthcare providers are adopting cognitive behavior therapy to improve menopause symptoms. This novel therapy is being highly publicized for not only treating hot flashes, but is also effective for other menopause symptoms. Companies in the menopausal hot flashes treatment market are creating awareness about cognitive behavior therapy, owing to its advantages of modifying dysfunctional emotions, behaviors and thoughts that enhance personal coping strategies. Since researchers have gained clinical success with the help of cognitive behavior therapy for the treatment of anxiety and depression, healthcare companies are expanding their healthcare services using the novel therapy.

Complications associated with menopausal hot flashes such as sleep disturbances and low-productivity levels in professional environments are increasing the demand for cognitive behavior therapy among patients. Long-term effectiveness of cognitive behavior therapy post treatment are creating lucrative opportunities for healthcare providers. Thus, healthcare companies are increasing efforts to conduct large-scale clinical trials in order to analyze its effectiveness in highly symptomatic women.

Analysts’ Viewpoint

Apart from innovations in medicines, alternative options such as weight-training and lifestyle modifications are proving to be effective for hot flashes. The hormone replacement therapy is highly popular in the menopausal hot flashes treatment market. However, controversies encircling the risk of blood clots, stroke, and some cancers pose a barrier for market growth. Hence, companies should tap opportunities in alternative treatment options such as cognitive behavior therapy, which is not only effective in the management of hot flashes, but also treats other symptoms such as anxiety and sleep disorders. Digitalization of health is another key driver contributing toward market growth, as femtech can target tech-savvy women through social media and innovative mobile apps.

Menopausal Hot Flashes Treatment Market: Overview

Menopause is defined as the permanent cessation of menses that may occur in as early as the thirties or as late as the sixties. The treatment and management of menopausal women has been a matter of great apprehension in the last few decades, both in terms of epidemiology and medical scientific research.

The most common menopausal symptoms, including vasomotor symptoms (menopausal hot flashes), insomnia, vaginal atrophy, altered cognitive function, dementia, depression, and loss of muscle mass, can affect up to 80% of women during menopause and may be severe in up to 20% of these women

Menopausal hot flashes symptoms treatment drugs are used to reduce hot flashes, which is a form of temperature dysfunction that occurs due to changes in gonadal hormones. Menopausal hot flashes symptom treatments are classified into hormonal treatment, non-hormonal treatment, and alternative treatment (including herbal products).

Hormonal treatment products are available in different dosage forms such as pill, patch, and gel. The use of hormone replacement therapy (HRT) alleviates menopausal hot flashes symptoms and leads to a major improvement in quality of life for women with menopausal hot flashes symptoms.

Growing population of elderly women worldwide coupled with rise in menopausal hot flashes symptoms is a major factor responsible for the growth of global menopausal hot flashes treatment market

Increase in awareness about women’s health due to different public as well as private organizations initiatives is also fueling the growth of global menopausal hot flashes treatment market

Moreover, development of advanced products with alternative mode of administration and changes in lifestyle associated with early menopause are some of the major factors attributed for the growth of global menopausal hot flashes treatment market

Market Segmentation: Menopausal Hot Flashes Treatment Market

Based on treatment type, the global menopausal hot flashes treatment market has been divided into hormonal treatment, non-hormonal treatment, and alternative treatment

Hormonal treatment is further classified into estrogen, progesterone, and estrogen – progesterone combination

The non-hormonal segment is sub-segmented into antidepressant, gabapentin, pregabalin, and clonidine. Antidepressant is further divided into Paroxetine, Fluoxetine, Vanlafaxine, Desvanlafaxine, and others.

Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111711/2900

The alternative segment is further sub-divided into black cohosh, vitamin E, herbal medicines, and others

Based on distribution channel, the global menopausal hot flashes treatment market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies

Each of the segments has been analyzed in detail for global menopausal hot flashes treatment market trends, recent trends, and developments, drivers, restraints, opportunities, and useful insights

The global menopausal hot flashes report provides current and future revenues (US$ Mn) for each these segments for the period from 2017 to 2027, considering 2018 as the base year. The compound annual growth rate (% CAGR) has been provided for each segment and market from 2019 to 2027 along with menopausal hot flashes market size estimations.

Regional Overview: Menopausal Hot Flashes Treatment Market

In terms of region, the global menopausal hot flashes treatment market has been divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions have been further divided into major countries and sub-regions.

The current and future market sizes for menopausal hot flashes treatment market in terms of revenue (US$ Mn) of these regional markets and their major countries have been provided in the report for the period from 2017 to 2027, with their CAGRs for the period from 2019 to 2027

The study also offers a list of recommendations, highlights, and useful insights of the global menopausal hot flashes treatment market which will help new companies willing to enter the market and existing companies to increase market shares, and help in the decision-making process

Major Players

The global menopausal hot flashes report concludes with the company profiles section that includes key information about the major players in the market

Key players analyzed in this global menopausal hot flashes treatment market include –

  • Pfizer Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Allergan plc
  • Teva Pharmaceutical Industries Ltd.
  • Mylan N.V.
  • Hisamitsu Pharmaceutical Co., Inc.
  • Merck & Co., Inc.
  • GlaxoSmithKline plc
  • TherapeuticsMD, Inc

Each of these players has been profiled in the menopausal hot flashes treatment market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments

Key Questions Answered in Menopausal Hot Flashes Treatment Market Report

  • What is the sales/revenue generated by each treatment type segment of the menopausal hot flashes treatment market across all regions during the forecast period?
  • What are the opportunities in the global menopausal hot flashes treatment market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which region is likely to expand at the fastest CAGR during the forecast period?
  • Which menopausal hot flashes treatment type and distribution channel segments are expected to generate the highest revenue globally in 2027? Which segment is projected to expand at the highest CAGR during the forecast period?
  • What is the market share or position of different companies operating in the global market in 2018?

Menopausal Hot Flashes Treatment Market – Segmentation

Treatment Type

  • Hormonal Treatment
  • Estrogen
  • Progesterone
  • Estrogen-Progesterone Combination
  • Non-hormonal Treatment
  • Antidepressant
  • Paroxetine
  • Fluoxetine
  • Venlafaxine
  • Desvenlafaxine
  • Others
  • Gabapentin
  • Pregabalin
  • Clonidine
  • Alternative Treatment
  • Black Cohosh
  • Vitamin E
  • Herbal Medicines
  • Others

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

TABLE OF CONTENT

1. Preface

1.1. Market Definition and Scope

1.2. Market Segmentation

1.3. Key Research Objectives

1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Menopausal Hot Flashes Treatment Market

4. Market Overview

4.1. Introduction

4.1.1. Product Type Definition

4.1.2. Industry Evolution / Developments

4.2. Overview

4.3. Market Dynamics

4.3.1. Drivers

4.3.2. Restraints

4.3.3. Opportunities

4.4. Global Menopausal Hot Flashes Treatment Market Analysis and Forecasts, 2017–2027

4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

5.1. Pipeline Analysis

5.2. Key Mergers, Acquisitions and Strategic Partnerships

5.3. Value Chain Analysis

6. Global Menopausal Hot Flashes Treatment Market Analysis and Forecasts, By Product Type

6.1. Introduction & Definition

6.2. Key Findings / Developments

6.3. Market Value Forecast By Product Type, 2017–2027

6.3.1. Hormonal Treatment

6.3.1.1. Estrogen

6.3.1.2. Progesterone

6.3.1.3. Estrogen-Progesterone Combination

6.3.2. Non-Hormonal Treatment

6.3.2.1. Antidepressant

6.3.2.1.1. Paroxetine

6.3.2.1.2. Fluoxetine

6.3.2.1.3. Venlafaxine

6.3.2.1.4. Desvenlafaxine

6.3.2.1.5. Others

6.3.2.2. Gabapentin

6.3.2.3. Progabalin

6.3.2.4. Clonidine

6.3.3. Alternative Treatment

6.3.3.1. Black Cohosh

6.3.3.2. Vitamin E

6.3.3.3. Herbal Medicines

6.3.3.4. Others

6.4. Market Attractiveness By Product Type, 2019-2027

7. Global Menopausal Hot Flashes Treatment Market Analysis and Forecasts, By Distribution Channel

7.1. Introduction & Definition

7.2. Key Findings / Developments

7.3. Market Value Forecast By Distribution Channel, 2017–2027

7.3.1. Hospital Pharmacies

7.3.2. Retail Pharmacies

7.3.3. Online Pharmacies

7.4. Market Attractiveness By Distribution Channel, 2019-2027

8. Global Menopausal Hot Flashes Treatment Market Analysis and Forecasts, By Region

8.1. Key Findings

8.2. Market Value Forecast By Region

8.2.1. North America

8.2.2. Europe

8.2.3. Asia Pacific

8.2.4. Latin America

8.2.5. Middle East & Africa

8.3. Market Attractiveness By Country/Region, 2019-2027

9. North America Menopausal Hot Flashes Treatment Market Analysis and Forecast

9.1. Introduction

9.1.1. Key Findings

9.2. Market Value Forecast By Product Type, 2017–2027

9.2.1. Hormonal Treatment

9.2.1.1. Estrogen

9.2.1.2. Progesterone

9.2.1.3. Estrogen-Progesterone Combination

9.2.2. Non-Hormonal Treatment

9.2.2.1. Antidepressant

9.2.2.1.1. Paroxetine

9.2.2.1.2. Fluoxetine

9.2.2.1.3. Venlafaxine

9.2.2.1.4. Desvenlafaxine

9.2.2.1.5. Others

9.2.2.2. Gabapentin

9.2.2.3. Progabalin

9.2.2.4. Clonidine

9.2.3. Alternative Treatment

9.2.3.1. Black Cohosh

9.2.3.2. Vitamin E

9.2.3.3. Herbal Medicines

9.2.3.4. Others

9.3. Market Value Forecast By Distribution Channel, 2017–2027

9.3.1. Hospital Pharmacies

9.3.2. Retail Pharmacies

9.3.3. Online Pharmacies

9.4. Market Value Forecast By Country, 2017–2027

9.4.1. U.S.

9.4.2. Canada

9.5. Market Attractiveness Analysis, 2019-2027

9.5.1. By Product Type

9.5.2. By Distribution Channel

9.5.3. By Country

10. Europe Menopausal Hot Flashes Treatment Market Analysis and Forecast

10.1. Introduction

10.1.1. Key Findings

10.2. Market Value Forecast By Product Type, 2017–2027

10.2.1. Hormonal Treatment

10.2.1.1. Estrogen

10.2.1.2. Progesterone

10.2.1.3. Estrogen-Progesterone Combination

10.2.2. Non-Hormonal Treatment

10.2.2.1. Antidepressant

10.2.2.1.1. Paroxetine

10.2.2.1.2. Fluoxetine

10.2.2.1.3. Venlafaxine

10.2.2.1.4. Desvenlafaxine

10.2.2.1.5. Others

10.2.2.2. Gabapentin

10.2.2.3. Progabalin

10.2.2.4. Clonidine

10.2.3. Alternative Treatment

10.2.3.1. Black Cohosh

10.2.3.2. Vitamin E

10.2.3.3. Herbal Medicines

10.2.3.4. Others

10.3. Market Value Forecast By Distribution Channel, 2017–2027

10.3.1. Hospital Pharmacies

10.3.2. Retail Pharmacies

10.3.3. Online Pharmacies

10.4. Market Value Forecast By Country, 2017–2027

10.4.1. Germany

10.4.2. U.K.

10.4.3. France

10.4.4. Spain

10.4.5. Italy

10.4.6. Rest of Europe

10.5. Market Attractiveness Analysis, 2019-2027

10.5.1. By Product Type

10.5.2. By Distribution Channel

10.5.3. By Country

11. Asia Pacific Menopausal Hot Flashes Treatment Market Analysis and Forecast

11.1. Introduction

11.1.1. Key Findings

11.2. Market Value Forecast By Product Type, 2017–2027

11.2.1. Hormonal Treatment

11.2.1.1. Estrogen

11.2.1.2. Progesterone

11.2.1.3. Estrogen-Progesterone Combination

11.2.2. Non-Hormonal Treatment

11.2.2.1. Antidepressant

11.2.2.1.1. Paroxetine

11.2.2.1.2. Fluoxetine

11.2.2.1.3. Venlafaxine

11.2.2.1.4. Desvenlafaxine

11.2.2.1.5. Others

11.2.2.2. Gabapentin

11.2.2.3. Progabalin

11.2.2.4. Clonidine

11.2.3. Alternative Treatment

11.2.3.1. Black Cohosh

11.2.3.2. Vitamin E

11.2.3.3. Herbal Medicines

11.2.3.4. Others

11.3. Market Value Forecast By Distribution Channel, 2017–2027

11.3.1. Hospital Pharmacies

11.3.2. Retail Pharmacies

11.3.3. Online Pharmacies

11.4. Market Value Forecast By Country, 2017–2027

11.4.1. China

11.4.2. Japan

11.4.3. India

11.4.4. Australia & New Zealand

11.4.5. Rest of Asia Pacific

11.5. Market Attractiveness Analysis, 2019-2027

11.5.1. By Product Type

11.5.2. By Distribution Channel

11.5.3. By Country

12. Latin America Menopausal Hot Flashes Treatment Market Analysis and Forecast

12.1. Introduction

12.1.1. Key Findings

12.2. Market Value Forecast By Product Type, 2017–2027

12.2.1. Hormonal Treatment

12.2.1.1. Estrogen

12.2.1.2. Progesterone

12.2.1.3. Estrogen-Progesterone Combination

12.2.2. Non-Hormonal Treatment

12.2.2.1. Antidepressant

12.2.2.1.1. Paroxetine

12.2.2.1.2. Fluoxetine

12.2.2.1.3. Venlafaxine

12.2.2.1.4. Desvenlafaxine

12.2.2.1.5. Others

12.2.2.2. Gabapentin

12.2.2.3. Progabalin

12.2.2.4. Clonidine

12.2.3. Alternative Treatment

12.2.3.1. Black Cohosh

12.2.3.2. Vitamin E

12.2.3.3. Herbal Medicines

12.2.3.4. Others

12.3. Market Value Forecast By Distribution Channel, 2017–2027

12.3.1. Hospital Pharmacies

12.3.2. Retail Pharmacies

12.3.3. Online Pharmacies

12.4. Market Value Forecast by Country, 2017–2027

12.4.1. Brazil

12.4.2. Mexico

12.4.3. Rest of Latin America

12.5. Market Attractiveness Analysis, 2019-2027

12.5.1. By Product Type

12.5.2. By Distribution Channel

12.5.3. By Country

13. Middle East & Africa Menopausal Hot Flashes Treatment Market Analysis and Forecast

13.1. Introduction

13.1.1. Key Findings

13.2. Market Value Forecast By Product Type, 2017–2027

13.2.1. Hormonal Treatment

13.2.1.1. Estrogen

13.2.1.2. Progesterone

13.2.1.3. Estrogen-Progesterone Combination

13.2.2. Non-Hormonal Treatment

13.2.2.1. Antidepressant

13.2.2.1.1. Paroxetine

13.2.2.1.2. Fluoxetine

13.2.2.1.3. Venlafaxine

13.2.2.1.4. Desvenlafaxine

13.2.2.1.5. Others

13.2.2.2. Gabapentin

13.2.2.3. Progabalin

13.2.2.4. Clonidine

13.2.3. Alternative Treatment

13.2.3.1. Black Cohosh

13.2.3.2. Vitamin E

13.2.3.3. Herbal Medicines

13.2.3.4. Others

13.3. Market Value Forecast By Distribution Channel, 2017–2027

13.3.1. Hospital Pharmacies

13.3.2. Retail Pharmacies

13.3.3. Online Pharmacies

13.4. Market Value Forecast By Country, 2017–2027

13.4.1. GCC Countries

13.4.2. South Africa

13.4.3. Rest of Middle East & Africa

13.5. Market Attractiveness Analysis, 2019-2027

13.5.1. By Product Type

13.5.2. By Distribution Channel

13.5.3. By Country

14. Competition Landscape

14.1. Market Player – Competition Matrix (By Tier and Size of companies)

14.2. Market Share/Position Analysis By Company (2018)

14.3. Company Profiles

14.3.1. Pfizer Inc.

14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

14.3.1.2. Company Financials

14.3.1.3. Growth Strategies

14.3.1.4. SWOT Analysis

14.3.2. Novartis AG

14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

14.3.2.2. Company Financials

14.3.2.3. Growth Strategies

14.3.2.4. SWOT Analysis

14.3.3. Novo Nordisk A/S

14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

14.3.3.2. Company Financials

14.3.3.3. Growth Strategies

14.3.3.4. SWOT Analysis

14.3.4. Allergan plc.

14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

14.3.4.2. Company Financials

14.3.4.3. Growth Strategies

14.3.4.4. SWOT Analysis

14.3.5. Teva Pharmaceutical Industries Ltd.

14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

14.3.5.2. Company Financials

14.3.5.3. Growth Strategies

14.3.5.4. SWOT Analysis

14.3.6. Mylan N.V.

14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

14.3.6.2. Company Financials

14.3.6.3. Growth Strategies

14.3.6.4. SWOT Analysis

14.3.7. Hisamitsu Pharmaceutical Co., Inc.

14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

14.3.7.2. Company Financials

14.3.7.3. Growth Strategies

14.3.7.4. SWOT Analysis

14.3.8. Merck & Co., Inc.

14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

14.3.8.2. Company Financials

14.3.8.3. Growth Strategies

14.3.8.4. SWOT Analysis

14.3.9. GlaxoSmithKline plc.

14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

14.3.9.2. Company Financials

14.3.9.3. Growth Strategies

14.3.9.4. SWOT Analysis

14.3.10. TherapeuticsMD, Inc.

14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

14.3.10.2. Company Financials

14.3.10.3. Growth Strategies

14.3.10.4. SWOT Analysis

Purchase Complete Report Now@  https://qyresearchmedical.com/report/checkout/111711/2900

You can place an order or ask any questions, please feel free to contact sales@qyresearchmedical.com | +1 9197 992 333

About Us

QYResearch Medical, focuses on custom research, management consulting, IPO consulting, industry chain research, and data base & seminar services. The company owns large basic databases (such as National Bureau of Statistics Database, Customs Import and Export Database, Industry Association Database, etc.), expert resources (including industry experts who own more than 10 years experiences on marketing or R&D in industries of healthcare services, medical technology & devices, etc.), professional survey team (the team members obtained more than 3 years market survey experience and more than 2 years deep expert interview experience), and excellent data analysis team (SPSS statistics and PPT graphics process team).

QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover China, US, EU, Asia, Middle East and Africa, South America, Australia, and other regions in the world.

For Latest Update Follow Us:

https://www.linkedin.com/company/qyresearch-medical/

https://www.facebook.com/QYResearch-Medical-108186514228917/

https://twitter.com/qyresearchmedi